Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin [trastuzumab] Therapy.

Trial Profile

Evaluation of Clinical Significance of Circulating Markers in Breast Cancer Patients Undergoing Herceptin [trastuzumab] Therapy.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 08 Jul 2015

At a glance

  • Drugs Trastuzumab (Primary)
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms HER2
  • Most Recent Events

    • 18 Jan 2012 Additional lead trial investigator (Kangerloo B) identified as reported by ClinicalTrials.gov.
    • 18 Jan 2012 Status changed from suspended to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 09 Jul 2010 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top